Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $36M (up 77.5% year over year) with net income of $38M.
Q1 2026 key financials · XBRL
- Revenue
- $36M
- +77.5% YoY
- Net income
- $38M
- +1322.7% YoY
- Operating margin
- 144.0%
- EPS (diluted)
- $0.60
- +1100.0% YoY
Source: XBRL data from the ZEVRA THERAPEUTICS, INC. (ZVRA) Q1 2026 10-Q on SEC EDGAR. USD.
ZEVRA THERAPEUTICS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $36.2M, up $15.8M YoY from $20.4M, driven by EAP revenue and MIPLYFFA sales
- Net income $37.9M vs $3.1M net loss YoY, including $43.3M gain on asset sales
- MIPLYFFA best performer, product sales up $7.5M; OLPRUVA revenue $0.3M with limited commercialization success
- Operating cash flow $6.1M vs $(8.2)M YoY; cash, equivalents and investments $236.8M
- Near-term outlook: significant expenses, minimal positive or negative operating cash flow, and OLPRUVA strategic alternatives evaluation
Risk Factors
- Newly added Medicaid risk triggered by July 2025 One Big Beautiful Bill Act, which reduces Medicaid funding and enrollment
- Most materially updated pricing risk from April 2026 Section 232 tariffs on brand pharmaceuticals, though orphan-designated MIPLYFFA is expected exempt
- Regulatory risk from proposed Globe and Guard regulations requiring Medicare rebates based on most-favored-nation pricing
- Market risk from state drug-pricing controls, including affordability boards and upper payment limits
- EU compliance risk from proposed reforms potentially reducing orphan-drug regulatory data and market protection; adoption not anticipated before early 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ZEVRA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.